The Pandemic's Effect on Diagnosis and Treatment of Rectal Cancer (CovidRC)

S

Sahlgrenska University Hospital

Status

Enrolling

Conditions

Rectal Cancer

Treatments

Other: Diagnosed during or not during the pandemic

Study type

Observational

Funder types

Other

Identifiers

NCT05328960
CovidRC

Details and patient eligibility

About

Colorectal cancer is common with an annual prevalence of 6000. The majority can be cured and the five year survival rate is over 60%. In december 2019 reports came in about SARS-Cov-2, which later was named Covid-19. The World Health Organization classified it as a pandemic in March 2020. In Sweden the number of patients with Covid-19 increased mainly in the urban areas in March 2020. Care for patients with other diseases were affected and local changes from guidelines were adopted. In some regions and countries the indications for adjuvant and neoadjuvant treatment for colorectal cancer were somewhat changed. The number of patients diagnosed with colorectal cancer also decreased, as well as other types of cancer. The true effect on outcome with a delayed diagnosis remains unknown. The aim of this study is to evaluate the effects of the Covid-19 pandemic on the diagnosis, treatment and survival of patients with colorectal cancer.

Enrollment

8,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Rectal cancer diagnosis 2019-2022

Exclusion criteria

  • No rectal cancer diagnosis 2019-2022

Trial design

8,000 participants in 1 patient group

Patients diagnosed before, during or after the pandemic
Description:
Patients with rectal cancer
Treatment:
Other: Diagnosed during or not during the pandemic

Trial contacts and locations

1

Loading...

Central trial contact

Anette Wedin, RN; Eva Angenete, MD. PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems